
### [MONDO:0016147](http://purl.obolibrary.org/obo/MONDO_0016147)
**Label:** qualitative or quantitative defects of dystrophin

**Subclasses:** [MONDO:0015470](http://purl.obolibrary.org/obo/MONDO_0015470) (familial isolated dilated cardiomyopathy), [MONDO:0010311](http://purl.obolibrary.org/obo/MONDO_0010311) (Becker muscular dystrophy), 

**Corr. equiv. classes:** [Orphanet:154](http://www.orpha.net/ORDO/Orphanet_154), [OMIM:300376](http://purl.obolibrary.org/obo/OMIM_300376), [Orphanet:98895](http://www.orpha.net/ORDO/Orphanet_98895), 

**Class expressions from DL-Learner:**

- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) 66.67%
- [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) and [HP:0040290](http://purl.obolibrary.org/obo/HP_0040290) (Abnormality of skeletal muscles) 66.67%
- [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) and [HP:0040083](http://purl.obolibrary.org/obo/HP_0040083) (Toe walking) 66.67%
- [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) and [HP:0040081](http://purl.obolibrary.org/obo/HP_0040081) (Abnormal levels of creatine kinase in blood) 66.67%
- [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) and [HP:0030236](http://purl.obolibrary.org/obo/HP_0030236) (Abnormality of muscle size) 66.67%
- [HP:0011021](http://purl.obolibrary.org/obo/HP_0011021) (Abnormality of circulating enzyme level) and [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) 66.67%
- [HP:0010876](http://purl.obolibrary.org/obo/HP_0010876) (Abnormality of circulating protein level) and [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) 66.67%
- [HP:0004302](http://purl.obolibrary.org/obo/HP_0004302) (Functional motor problems) and [HP:0012086](http://purl.obolibrary.org/obo/HP_0012086) (Abnormal urinary color) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0040081](http://purl.obolibrary.org/obo/HP_0040081) (Abnormal levels of creatine kinase in blood) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0030956](http://purl.obolibrary.org/obo/HP_0030956) (Abnormality of cardiovascular system electrophysiology) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0030680](http://purl.obolibrary.org/obo/HP_0030680) (Abnormality of cardiovascular system morphology) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0025142](http://purl.obolibrary.org/obo/HP_0025142) (Constitutional symptom) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0012823](http://purl.obolibrary.org/obo/HP_0012823) (Clinical modifier) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) 66.67%
- [HP:0003707](http://purl.obolibrary.org/obo/HP_0003707) (Calf muscle pseudohypertrophy) and [HP:0012531](http://purl.obolibrary.org/obo/HP_0012531) (Pain) 66.67%


